KT 362

Drug Profile

KT 362

Latest Information Update: 05 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kotobuki Seiyaku
  • Class Anti-ischaemics; Antiarrhythmics; Antihypertensives; Ischaemic heart disorder therapies; Small molecules; Thiazepines
  • Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Hypertension; Ischaemic heart disorders

Most Recent Events

  • 01 Aug 1997 Suspended-I for Hypertension in USA (Unknown route)
  • 25 Mar 1997 Discontinued-II for Hypertension in Japan (Unknown route)
  • 25 Mar 1997 Discontinued-II for Ischaemic heart disorders in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top